Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company pioneering precision therapies for patients with genetically defined diseases. This dedicated news hub provides investors and researchers with essential updates on the company's innovative programs targeting systemic mastocytosis, GIST, and other mutation-driven conditions.
Access real-time information about bezuclastinib clinical trials, including the SUMMIT (NonAdvSM), APEX (AdvSM), and PEAK (GIST) studies. Stay informed on pipeline developments across Cogent's portfolio of selective kinase inhibitors, from FGFR2-targeted therapies to novel KRAS(ON) inhibitors in preclinical testing.
Our curated news collection features official press releases, regulatory filings, and scientific presentation updates. Key content categories include clinical trial milestones, research collaborations, and therapeutic development progress – all critical for understanding Cogent's position in the precision medicine landscape.
Bookmark this page for streamlined access to verified COGT updates. Investors can monitor the company's advancement of potentially transformative therapies while researchers track developments in mutation-specific treatment approaches.
Cogent Biosciences has announced positive updated lead-in data from its ongoing Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib for treating gastrointestinal stromal tumors (GIST). The combination achieved a median progression-free survival (mPFS) of 19.4 months and a 33% objective response rate (ORR) in a subset of patients. The data will be presented at the ASCO Annual Meeting on June 1, 2024.
In addition, Cogent announced a new Phase 2 trial of bezuclastinib plus sunitinib, sponsored by the Sarcoma Alliance for Research through Collaboration (SARC), targeting later-line GIST patients. Enrollment in the PEAK trial is ahead of schedule, now expected to be completed in Q3 2024. The treatment continues to show a favorable safety profile.
Cogent Biosciences, Inc. (Nasdaq: COGT) reported on track clinical trial enrollment for three studies with topline results expected in 2025. The company ended the first quarter of 2024 with $435.7 million in cash, sufficient to fund operations until 2027. Recent business highlights include positive clinical data from SUMMIT trial and oversubscribed private placement.
FAQ
What is the current stock price of Cogent Biosciences (COGT)?
What is the market cap of Cogent Biosciences (COGT)?
